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Letter to the Editor
Pediatric high-grade glioma 
resources from the Children’s 
Brain Tumor Tissue Consortium 
Pediatric high-grade gliomas (pHGGs) are a leading cause of pe-
diatric cancer death but are genomically and spatially distinct.1,2 
In this report we describe the generation and characterization of 
pHGG reagents with linked genomic and longitudinal clinical data 
freely available to the community to accelerate pHGG research.3
The pHGG biospecimen collection, annotation, genomic 
sequencing, and cell line generation were coordinated by the 
Children’s Brain Tumor Tissue Consortium (CBTTC) (https://
cbttc.org), which is an international, collaborative, multi-
institutional research program dedicated to the study of 
childhood brain tumors. After project proposal approval, the 
specimens are delivered to investigators while CBTTC data 
are available for viewing and download from the Gabriella 
Miller Kids First Data Resource Center (KF-DRC, https://
kidsfirstdrc.org) or as processed data in PedcBioPortal (https://
pedcbioportal.org). All subjects consented to tissue and data 
collection through CBTTC Institutional Review Board–ap-
proved protocols. The KF-DRC is recognized as a National 
Institutes of Health Trusted Partner for data sharing protections.
The CBTTC cohort of pHGG primary tumors represents the 
spectrum of disease. The clinical covariates, genomics, and 
biospecimens of the pHGG set in this study are shown in Figure 
1. The cohort with tumor whole genome sequencing represents 
73 participants. Tumors were from participants with a median 
age of 9 years at diagnosis and 55% were female. Sixty percent 
were from initial or diagnostic specimens and 46% were from 
a hemispheric location. Analysis of a selected set of recurrently 
mutated pHGG genes was of an expected distribution with 
47% TP53, 36% H3.3, 24% ATRX, and 7% BRAF V600E variants.2 
Tumors had mutually exclusive H3.3 G34 and K27M mutations 
and co-occurring mutations of ATRX with H3.3 G34R or NF1.4,5 
Seven participants’ tumors demonstrated features of hypermu-
tation with somatic and/or germline mismatch repair deficiency.6
At the time of study initiation, the CBTTC biorepository had 
37 pHGG tumor tissues stored in freezing media that were dis-
sociated and cultured with 4 different culturing conditions. At 
least one culture grew from 23/37 (62%) dissociation events 
from 23/73 (31%) patients in our cohort. Patient derived cell 
line information including prior patient therapy, culture, and 
growing conditions, including orthotopic xenografts, doubling 
times, and validation status are described elsewhere.3 The cell 
line panel represents the spectrum of pHGG genomics with 8 
unique patient cell lines with H3.3 mutations (35%), 6 with TP53 
mutations (26%), 1 with a BRAF V600E mutation, and 1 with a 
KRAS Q61H mutation. Three patient cell lines were derived from 
tumors with mismatch repair deficiency and hypermutation.
For each of the tumors in the CBTTC there are additional 
banked biospecimens including tumor tissue, tumor in freezing 
media, blood, plasma, cerebrospinal fluid, and both tumor and 
blood derived nucleic acids (https://cbttc.org). Of the pHGG 
cohort in this study, 36 patient tumors are also available on 
a tissue microarray. This valuable resource will enable re-
searchers to examine the tumor microenvironment, discover 
cell surface immunotherapy target proteins, or perform valida-
tion studies of the corresponding proteomic dataset. Finally, to 
facilitate integrative studies, most of the tumors in the pHGG set 
have corresponding redacted operative reports and pathology 
and radiology reports, along with the relevant MRI images 
and histology slides. Supplementary Figure 1 shows reagents 
for patient PT_9BZETMOM (7316-158 and 7316-5317), whose di-
agnosis and relapse tumors have the rare H3.3 G34R mutation.
In summary, the CBTTC with its member institutions, donors, 
patients, and families has developed an infrastructure to support 
pHGG research for both large genomic projects and individual 
laboratories. The CBTTC pHGG patient tumors and associated 
datasets are expected to increase, which when integrated with 
adult cancer and other disease sets promise to advance discov-
eries and hope of effective therapies for this devastating disease.
Supplementary Material
Supplementary data are available at Neuro-Oncology online.
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Low = 0–10 mut/Mb
High = 10–100 mut/Mb



























































































































































































































































































































































































































































































































































































































































Fig. 1 The CBTTC pHGG cohort. OncoPrint of the clinical covariates, genomics, and resources of the pHGG cohort. dx = diagnosis; recc = recur-
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